PM Consulting Group Changes Name to Vistant
One of the Fastest Growing Companies in Washington, DC, and Baltimore, Rebrands and Reaffirms Commitment To Helping Solve Complex Global...
One of the Fastest Growing Companies in Washington, DC, and Baltimore, Rebrands and Reaffirms Commitment To Helping Solve Complex Global...
LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty...
Treatments are comfortable, highly effective and with a fast recovery Patient undergoing gingival recontouring laser treatment with Spectralase at Smile...
The Industry’s Only SaaS Solution for the Coordination of Multiple Concurrent Patient Engagement Initiatives to Optimize Impact and EfficiencyBOWIE, Md.,...
Philips Intracardiac Echocardiography Catheter – VeriSight Pro Intravascular ultrasound (IVUS) catheter CIED infection March 6, 2023 Preliminary results of large-scale...
GUILFORD, Conn., March 06, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the...
Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity...
WINTER SPRINGS, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi,...
Live conference call on Friday, March 10 at 8:30 a.m. ETMIAMI, March 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:...
MINNEAPOLIS, March 06, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
WARREN, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics...
Company on track to achieve target cash savings of $30 - $35 million in 2023 vs 2022; expects to report...
Figure 1 Fluoresceine angiogram data from three animals treated with NM3086 (bottom) and three that received placebo control. The picture...
Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension Obesity was predictive of an enhanced response to...
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless...
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular...
Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive HCM, Supporting Advancement...
Into the Dark Into the Dark Campaign ImageEmphasizes challenges faced by patients and clinicians within the first 30 days after...
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, March 03, 2023 (GLOBE...
NEWS RELEASE – REGULATED INFORMATIONMARCH 3, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 3,...